In Hwan Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
In Hwan Hong has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
In Boem Chang
Seoul On Eye Clinic, Seoul, Korea
5 shared publicationsIn Hwan Cho
Department of Ophthalmology Soonchunhyang University Hospital Cheonan, Soonchunhyang University College of Medicine Cheonan Republic of Korea
4 shared publicationsDae Joong Ma
Department of Ophthalmology, Kangnam Sacred Heart Hospital, Seoul, Republic of Korea
3 shared publicationsSe Hyun Choi
Department of Ophthalmology, Hallym University Sacred Heart Hospital, Anyang-si, South Korea
3 shared publicationsGang Seok Jeon
Dasan Samsung Bright Eye Clinic, Gyeonggi-do, Korea
2 shared publicationsHo Seok Lee
Department of Ophthalmology, Dongtan Sacred Heart Hospital, Hallym University Medical Center, Hwaseong-si, Gyeonggi-do, Korea
2 shared publications
Latest Publications
- Open Access
- 8 July 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 104 (1) , e39-e47
Continuity of care and risk of vision loss in patients with newly developed macular degeneration
Purpose: Neovascular age‐related macular degeneration (AMD) is a major cause of vision loss. Effective treatment requires sustained care, which may be influenced by continuity of care (COC). Understanding this association is crucial for improving patient outcomes. We investigated the association between COC and the risk of visual impairment in patients newly diagnosed with neovascular AMD. Methods: This nationwide cohort study sourced data from the South Korean National Health Insurance Service database (2014–2021). In total, 15 563 (6210 females) newly diagnosed patients with neovascular AMD were included. The COC index, based on the frequency of ophthalmology visits over the first 2 years post‐diagnosis, was assessed; a threshold of 0.75 was used to define good continuity. The primary outcome was visual impairment. Statistical models were used to assess the association between COC and the visual impairment risk, with adjustment for relevant confounding variables. Results: Patients with a bad COC index had a significantly higher cumulative incidence (6.86% vs. 4.78%) and a higher incidence rate of visual impairment (909 vs. 704 cases per 100 000 person‐years; 95% confidence interval, 764.0–1080.4, p < 0.001). This elevated risk was especially notable for female patients, patients aged ≥70 years, and patients with lower comorbidity burdens. Conclusions: Poor COC is associated with increased visual impairment risk in patients with neovascular AMD. Strategies to improve COC may reduce this risk, particularly among older adults and high‐risk groups.
- 8 July 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 104 (1) , e39-e47
Open AccessContinuity of care and risk of vision loss in patients with newly developed macular degeneration
Purpose: Neovascular age‐related macular degeneration (AMD) is a major cause of vision loss. Effective treatment requires sustained care, which may be influenced by continuity of care (COC). Understanding this association is crucial for improving patient outcomes. We investigated the association between COC and the risk of visual impairment in patients newly diagnosed with neovascular AMD. Methods: This nationwide cohort study sourced data from the South Korean National Health Insurance Service database (2014–2021). In total, 15 563 (6210 females) newly diagnosed patients with neovascular AMD were included. The COC index, based on the frequency of ophthalmology visits over the first 2 years post‐diagnosis, was assessed; a threshold of 0.75 was used to define good continuity. The primary outcome was visual impairment. Statistical models were used to assess the association between COC and the visual impairment risk, with adjustment for relevant confounding variables. Results: Patients with a bad COC index had a significantly higher cumulative incidence (6.86% vs. 4.78%) and a higher incidence rate of visual impairment (909 vs. 704 cases per 100 000 person‐years; 95% confidence interval, 764.0–1080.4, p < 0.001). This elevated risk was especially notable for female patients, patients aged ≥70 years, and patients with lower comorbidity burdens. Conclusions: Poor COC is associated with increased visual impairment risk in patients with neovascular AMD. Strategies to improve COC may reduce this risk, particularly among older adults and high‐risk groups.
- Open Access
- 10 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-8
A comprehensive evaluation of efficacy of hyperbaric oxygen therapy in non-arteritic central retinal artery occlusion using enhanced depth imaging optical coherence tomography
This study aimed to assess the efficacy of hyperbaric oxygen therapy (HBOT) in patients with central retinal artery occlusion (CRAO) by analyzing changes in visual acuity (VA) and enhanced depth imaging optical coherence tomography (EDI-OCT) parameters. A comparative retrospective study was conducted by reviewing the medical records of all HBO-treated RAO patients in our department and comparing them with matched RAO patients who did not receive HBO treatment. All patients treated with HBO received treatment within 7 days of the onset of visual symptoms. Baseline characteristics were compared, and VA and OCT parameters were evaluated at baseline and follow-up visits. A total of 50 eyes from 50 patients were included, with 29 eyes in the HBOT group and 21 eyes in the control group. The mean BCVA of the HBOT group at the initial visit was 2.03 logMAR, which improved to 1.55 logMAR at 6 months, with the change being statistically significant (P < 0.01), while the control group's BCVA remained almost unchanged, from 2.1 to 2.11 logMAR (P = 0.762). The central choroidal thickness increased significantly in the HBOT group over the subsequent period. The central fovea, and outer retinal layer thickness in the HBOT group were significantly greater than those in the control group at the 6-month follow-up after treatment. HBOT appears to be effective in improving VA and inducing favorable changes in OCT parameters in patients with CRAO. It helps to preserve retinal layer thickness, especially in the outer retinal layer.
- 10 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-8
Open AccessA comprehensive evaluation of efficacy of hyperbaric oxygen therapy in non-arteritic central retinal artery occlusion using enhanced depth imaging optical coherence tomography
This study aimed to assess the efficacy of hyperbaric oxygen therapy (HBOT) in patients with central retinal artery occlusion (CRAO) by analyzing changes in visual acuity (VA) and enhanced depth imaging optical coherence tomography (EDI-OCT) parameters. A comparative retrospective study was conducted by reviewing the medical records of all HBO-treated RAO patients in our department and comparing them with matched RAO patients who did not receive HBO treatment. All patients treated with HBO received treatment within 7 days of the onset of visual symptoms. Baseline characteristics were compared, and VA and OCT parameters were evaluated at baseline and follow-up visits. A total of 50 eyes from 50 patients were included, with 29 eyes in the HBOT group and 21 eyes in the control group. The mean BCVA of the HBOT group at the initial visit was 2.03 logMAR, which improved to 1.55 logMAR at 6 months, with the change being statistically significant (P < 0.01), while the control group's BCVA remained almost unchanged, from 2.1 to 2.11 logMAR (P = 0.762). The central choroidal thickness increased significantly in the HBOT group over the subsequent period. The central fovea, and outer retinal layer thickness in the HBOT group were significantly greater than those in the control group at the 6-month follow-up after treatment. HBOT appears to be effective in improving VA and inducing favorable changes in OCT parameters in patients with CRAO. It helps to preserve retinal layer thickness, especially in the outer retinal layer.
- Open Access
- 18 March 2024
- Published by S. Karger AG in Ophthalmic Research
- Vol. 67 (1) , 221-231
Comparative Evaluation of Visual Outcomes in Combined Cataract and Vitrectomy for Idiopathic Epiretinal Membrane with an Advanced or Conventional Intraocular Lens
Introduction: The aim of this study was to investigate the efficacy of new monofocal intraocular lens (IOL) in comparison with conventional monofocal IOL in patients undergoing combined cataract and vitrectomy surgery for epiretinal membrane (ERM). Methods: This prospective non-randomized comparative study included 65 eyes of 65 patients who underwent combined cataract and vitrectomy for ERM with implantation of advanced monofocal IOL (Eyhance ICB00, 33 patients) and standard monofocal IOL (Tecnis ZCB00, 32 patients). Monocular visual acuities were measured 6 months post-operatively, including corrected and uncorrected distance visual acuity (CDVA, UCDVA), uncorrected intermediate visual acuity (UCIVA), and uncorrected near visual acuity (UCNVA). Furthermore, contrast sensitivity and metamorphopsia were measured. Results: There was no significant difference between two groups regarding operation time, post-operative CDVA, UCDVA, UCNVA, and spherical equivalent (p > 0.05). Monocular UCIVA was significantly higher in the Eyhance IOL group than in the Tecnis IOL group (p = 0.005). The photopic and mesopic contrast sensitivities were comparable between each group for any spatial frequency (p > 0.05). The correlation coefficients from correlations between retinal wrinkling ratio and M score did not differ significantly between groups (p = 0.877), and the degree of metamorphopsia was not significantly related to the type of IOL (p = 0.969). Conclusions: In combined cataract and vitrectomy for ERM, Eyhance IOL provided significant better visual performance at intermediate distance than standard monofocal IOL without compromising operation time, distance vision, contrast sensitivity, and evaluating metamorphopsia. Eyhance IOL can be a useful option for both surgeons and patients.
- 18 March 2024
- Published by S. Karger AG in Ophthalmic Research
- Vol. 67 (1) , 221-231
Open AccessComparative Evaluation of Visual Outcomes in Combined Cataract and Vitrectomy for Idiopathic Epiretinal Membrane with an Advanced or Conventional Intraocular Lens
Introduction: The aim of this study was to investigate the efficacy of new monofocal intraocular lens (IOL) in comparison with conventional monofocal IOL in patients undergoing combined cataract and vitrectomy surgery for epiretinal membrane (ERM). Methods: This prospective non-randomized comparative study included 65 eyes of 65 patients who underwent combined cataract and vitrectomy for ERM with implantation of advanced monofocal IOL (Eyhance ICB00, 33 patients) and standard monofocal IOL (Tecnis ZCB00, 32 patients). Monocular visual acuities were measured 6 months post-operatively, including corrected and uncorrected distance visual acuity (CDVA, UCDVA), uncorrected intermediate visual acuity (UCIVA), and uncorrected near visual acuity (UCNVA). Furthermore, contrast sensitivity and metamorphopsia were measured. Results: There was no significant difference between two groups regarding operation time, post-operative CDVA, UCDVA, UCNVA, and spherical equivalent (p > 0.05). Monocular UCIVA was significantly higher in the Eyhance IOL group than in the Tecnis IOL group (p = 0.005). The photopic and mesopic contrast sensitivities were comparable between each group for any spatial frequency (p > 0.05). The correlation coefficients from correlations between retinal wrinkling ratio and M score did not differ significantly between groups (p = 0.877), and the degree of metamorphopsia was not significantly related to the type of IOL (p = 0.969). Conclusions: In combined cataract and vitrectomy for ERM, Eyhance IOL provided significant better visual performance at intermediate distance than standard monofocal IOL without compromising operation time, distance vision, contrast sensitivity, and evaluating metamorphopsia. Eyhance IOL can be a useful option for both surgeons and patients.
- Open Access
- 5 October 2023
- Published by Korean Ophthalmological Society in Korean Journal of Ophthalmology
- Vol. 37 (5) , 401-408
Improved Intermediate Visual Function with New Monofocal Intraocular Lens in Combined Cataract and Vitrectomy Surgery for Retinal Disease
Purpose: To evaluate the usefulness of a newly generated monofocal intraocular lens (IOL) in patients with various retinal diseases who underwent combined cataract and pars plana vitrectomy surgery.Methods: This prospective observational study included 33 patients with various retinal diseases. Monocular best-corrected distance visual acuity (BCDVA), uncorrected distance visual acuity (UCDVA), uncorrected intermediate visual acuity (UCIVA), uncorrected near visual acuity (UCNVA), and contrast sensitivity were measured and compared with 40 age-matched patients in the standard monofocal IOL.Results: The Eyhance IOL group demonstrated significantly better UCIVA at 6 months follow-up compared to the standard monofocal IOL group. No significant differences were observed between the two groups in contrast sensitivity, BCDVA, UCDVA, or UCNVA. The regression analysis showed a significant association between preoperative corrected distance visual acuity and improved UCIVA in the Eyhance IOL group.Conclusions: The Eyhance ICB00 IOL proved to be a valuable option for patients with retinal diseases undergoing combined cataract surgery and vitrectomy. It effectively improved intermediate vision without compromising contrast sensitivity or distance visual acuity.
- 5 October 2023
- Published by Korean Ophthalmological Society in Korean Journal of Ophthalmology
- Vol. 37 (5) , 401-408
Open AccessImproved Intermediate Visual Function with New Monofocal Intraocular Lens in Combined Cataract and Vitrectomy Surgery for Retinal Disease
Purpose: To evaluate the usefulness of a newly generated monofocal intraocular lens (IOL) in patients with various retinal diseases who underwent combined cataract and pars plana vitrectomy surgery.Methods: This prospective observational study included 33 patients with various retinal diseases. Monocular best-corrected distance visual acuity (BCDVA), uncorrected distance visual acuity (UCDVA), uncorrected intermediate visual acuity (UCIVA), uncorrected near visual acuity (UCNVA), and contrast sensitivity were measured and compared with 40 age-matched patients in the standard monofocal IOL.Results: The Eyhance IOL group demonstrated significantly better UCIVA at 6 months follow-up compared to the standard monofocal IOL group. No significant differences were observed between the two groups in contrast sensitivity, BCDVA, UCDVA, or UCNVA. The regression analysis showed a significant association between preoperative corrected distance visual acuity and improved UCIVA in the Eyhance IOL group.Conclusions: The Eyhance ICB00 IOL proved to be a valuable option for patients with retinal diseases undergoing combined cataract surgery and vitrectomy. It effectively improved intermediate vision without compromising contrast sensitivity or distance visual acuity.
- 29 June 2023
- Published by Taylor & Francis in Current Eye Research
- Vol. 48 (10) , 904-910
Evaluation of a New Monofocal Intraocular Lens in Patients Undergoing Cataract and Vitrectomy Surgery for Idiopathic Macular Hole
PurposeTo evaluate the usefulness of a newly generated monofocal intraocular lens (IOL) in patients who underwent combined cataract and pars plana vitrectomy (PPV) surgery for idiopathic macular hole (MH).MethodsA prospective study was conducted on 89 eyes of 89 patients who underwent combined cataract and PPV surgery for MH. The patients were divided into two groups: Eyhance ICB00 and Tecnis ZCB00. Pre-operative characteristics, post-operative visual outcomes, contrast sensitivity, and complications were compared between the two groups. A univariate regression analysis was performed to identify the factors that may affect the postoperative visual outcomes.ResultsBoth groups showed significant improvement in mean corrected distance visual acuity (CDVA) six months post-operation (p < 0.001). There was no significant difference in pre-operative characteristics or complications between the two groups. However, the Eyhance ICB00 group showed a significantly higher uncorrected intermediate visual acuity (UCIVA) value at 6 months after surgery than the Tecnis ZCB00 group (p = 0.014). Contrast sensitivity values were not significantly different between the two groups. The univariate regression analysis revealed a significant correlation between preoperative CDVA and minimum linear diameter of MH with postoperative UCIVA in the Eyhance ICB00 group.ConclusionsThe newly generated Eyhance ICB00 IOL showed promising results in terms of post-operative UCIVA, with no significant difference in complications or contrast sensitivity values compared to the Tecnis ZCB00 IOL. These findings suggest that the Eyhance ICB00 IOL may be a useful option for patients who undergo combined cataract and PPV surgery for idiopathic MH, particularly for those who require intermediate visual acuity.
- 29 June 2023
- Published by Taylor & Francis in Current Eye Research
- Vol. 48 (10) , 904-910
Evaluation of a New Monofocal Intraocular Lens in Patients Undergoing Cataract and Vitrectomy Surgery for Idiopathic Macular Hole
PurposeTo evaluate the usefulness of a newly generated monofocal intraocular lens (IOL) in patients who underwent combined cataract and pars plana vitrectomy (PPV) surgery for idiopathic macular hole (MH).MethodsA prospective study was conducted on 89 eyes of 89 patients who underwent combined cataract and PPV surgery for MH. The patients were divided into two groups: Eyhance ICB00 and Tecnis ZCB00. Pre-operative characteristics, post-operative visual outcomes, contrast sensitivity, and complications were compared between the two groups. A univariate regression analysis was performed to identify the factors that may affect the postoperative visual outcomes.ResultsBoth groups showed significant improvement in mean corrected distance visual acuity (CDVA) six months post-operation (p < 0.001). There was no significant difference in pre-operative characteristics or complications between the two groups. However, the Eyhance ICB00 group showed a significantly higher uncorrected intermediate visual acuity (UCIVA) value at 6 months after surgery than the Tecnis ZCB00 group (p = 0.014). Contrast sensitivity values were not significantly different between the two groups. The univariate regression analysis revealed a significant correlation between preoperative CDVA and minimum linear diameter of MH with postoperative UCIVA in the Eyhance ICB00 group.ConclusionsThe newly generated Eyhance ICB00 IOL showed promising results in terms of post-operative UCIVA, with no significant difference in complications or contrast sensitivity values compared to the Tecnis ZCB00 IOL. These findings suggest that the Eyhance ICB00 IOL may be a useful option for patients who undergo combined cataract and PPV surgery for idiopathic MH, particularly for those who require intermediate visual acuity.
- 18 June 2023
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 16 (6) , 909-914
Volumetric fluid analysis of fixed monthly anti-VEGF treatment in patients with neovascular age-related macular degeneration
? AIM: To evaluate visual outcomes and changes in fluid after administering monthly anti-vascular endothelial growth factor (VEGF) injections to treat neovascular age -related macular degeneration (nAMD) with subretinal fluid (SRF) and pigment epithelial detachment (PED).? METHODS: This prospective study included eyes with nAMD previously treated with as-needed anti-VEGF injections. The patients were treated with six monthly intravitreal injections of ranibizumab. Quantitative volumetric segmentation analyses of the SRF and PED were performed. The main outcome measures included best-corrected visual acuity (BCVA), and SRF and PED volumes.? RESULTS: Twenty eyes of 20 patients were included in this study. At the 6-month follow-up, BCVA and PED volume did not change significantly (P=0.110 and 0.999, respectively) but the mean SRF volume decreased from 0.53 & PLUSMN;0.82 mm3 at baseline to 0.08 & PLUSMN;0.23 mm3 (P=0.002). The absorption rate of the SRF volume was negatively correlated with the duration of previous anti-VEGF treatment (P=0.029). Seven of the 20 eyes (35%) showed a fluid-free macula and significant improvement in BCVA (P=0.036) by month 6.? CONCLUSION: Quantifying the SRF can precisely determine the patient's responsiveness to anti-VEGF treatment of nAMD.
- 18 June 2023
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 16 (6) , 909-914
Volumetric fluid analysis of fixed monthly anti-VEGF treatment in patients with neovascular age-related macular degeneration
? AIM: To evaluate visual outcomes and changes in fluid after administering monthly anti-vascular endothelial growth factor (VEGF) injections to treat neovascular age -related macular degeneration (nAMD) with subretinal fluid (SRF) and pigment epithelial detachment (PED).? METHODS: This prospective study included eyes with nAMD previously treated with as-needed anti-VEGF injections. The patients were treated with six monthly intravitreal injections of ranibizumab. Quantitative volumetric segmentation analyses of the SRF and PED were performed. The main outcome measures included best-corrected visual acuity (BCVA), and SRF and PED volumes.? RESULTS: Twenty eyes of 20 patients were included in this study. At the 6-month follow-up, BCVA and PED volume did not change significantly (P=0.110 and 0.999, respectively) but the mean SRF volume decreased from 0.53 & PLUSMN;0.82 mm3 at baseline to 0.08 & PLUSMN;0.23 mm3 (P=0.002). The absorption rate of the SRF volume was negatively correlated with the duration of previous anti-VEGF treatment (P=0.029). Seven of the 20 eyes (35%) showed a fluid-free macula and significant improvement in BCVA (P=0.036) by month 6.? CONCLUSION: Quantifying the SRF can precisely determine the patient's responsiveness to anti-VEGF treatment of nAMD.
- Open Access
- 24 March 2023
- Published by S. Karger AG in Ophthalmic Research
- Vol. 66 (1) , 816-823
Multifocal Electroretinography Changes over 12 Months after Resolution of Central Serous Chorioretinopathy: Prospective Observational Study
Introduction: This prospective observational study aimed to evaluate the changes in retinal function after the anatomical resolution of central serous chorioretinopathy by multifocal electroretinography. Methods: Thirty-two eyes of 32 patients with unilaterally resolved central serous chorioretinopathy were prospectively studied. Serial multifocal electroretinography examinations were performed at the initial visit for active central serous chorioretinopathy, the time of anatomical resolution (resolved central serous chorioretinopathy), and 3, 6, and 12 months after resolution. The peak amplitudes of the first kernel responses were analysed and compared with those in 27 age-matched normal controls. Results: Compared with controls, the N1 amplitudes of rings 1–4 and P1 amplitudes of rings 1–3 showed statistically significant reductions at 12 months after the resolution of central serous chorioretinopathy (p < 0.05). The multifocal electroretinography amplitude substantially increased at the time of resolution and gradually improved until 3 months after the resolution of central serous chorioretinopathy. Conclusion: Serial examinations with multifocal electroretinography showed that retinal responses increased mostly after the resolution of central serous chorioretinopathy, and this improvement slowly progressed until 3 months; however, the multifocal electroretinography amplitudes remained statistically reduced 12 months after the anatomical resolution of central serous chorioretinopathy, indicating the residual functional deficits detected by multifocal electroretinography.
- 24 March 2023
- Published by S. Karger AG in Ophthalmic Research
- Vol. 66 (1) , 816-823
Open AccessMultifocal Electroretinography Changes over 12 Months after Resolution of Central Serous Chorioretinopathy: Prospective Observational Study
Introduction: This prospective observational study aimed to evaluate the changes in retinal function after the anatomical resolution of central serous chorioretinopathy by multifocal electroretinography. Methods: Thirty-two eyes of 32 patients with unilaterally resolved central serous chorioretinopathy were prospectively studied. Serial multifocal electroretinography examinations were performed at the initial visit for active central serous chorioretinopathy, the time of anatomical resolution (resolved central serous chorioretinopathy), and 3, 6, and 12 months after resolution. The peak amplitudes of the first kernel responses were analysed and compared with those in 27 age-matched normal controls. Results: Compared with controls, the N1 amplitudes of rings 1–4 and P1 amplitudes of rings 1–3 showed statistically significant reductions at 12 months after the resolution of central serous chorioretinopathy (p < 0.05). The multifocal electroretinography amplitude substantially increased at the time of resolution and gradually improved until 3 months after the resolution of central serous chorioretinopathy. Conclusion: Serial examinations with multifocal electroretinography showed that retinal responses increased mostly after the resolution of central serous chorioretinopathy, and this improvement slowly progressed until 3 months; however, the multifocal electroretinography amplitudes remained statistically reduced 12 months after the anatomical resolution of central serous chorioretinopathy, indicating the residual functional deficits detected by multifocal electroretinography.
- Open Access
- 1 November 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (6) , 683-687
Molecular Epidemiology of Adenoviral Keratoconjunctivitis in Korea
Jeong-Won Seo , M.D., Su Kyung Lee , M.S., In Hwan Hong , M.D., Se Hyun Choi , M.D., Joo Youn Lee , M.D., Han-Sung Kim , M.D., and Hyun Soo Kim , M.D.. Ann Lab Med 2022;42:683-7. https://doi.org/10.3343/alm.2022.42.6.683
- 1 November 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (6) , 683-687
Open AccessMolecular Epidemiology of Adenoviral Keratoconjunctivitis in Korea
Jeong-Won Seo , M.D., Su Kyung Lee , M.S., In Hwan Hong , M.D., Se Hyun Choi , M.D., Joo Youn Lee , M.D., Han-Sung Kim , M.D., and Hyun Soo Kim , M.D.. Ann Lab Med 2022;42:683-7. https://doi.org/10.3343/alm.2022.42.6.683
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (49)
Incidence and Prevalence of Pediatric Noninfectious Uveitis in Korea: A Population-Based Study
Kim BH, et al. J Korean Med Sci. 2022 Nov;37(49):e344. https://doi.org/10.3346/jkms.2022.37.e344
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (49)
Open AccessIncidence and Prevalence of Pediatric Noninfectious Uveitis in Korea: A Population-Based Study
Kim BH, et al. J Korean Med Sci. 2022 Nov;37(49):e344. https://doi.org/10.3346/jkms.2022.37.e344
- Open Access
- 25 December 2021
- Published by The Korean Optometry Society and The Korean Contact Lens Study Society in Annals of Optometry and Contact Lens
- Vol. 20 (4) , 164-168
Bi-weekly Subconjunctival Injection of Bevacizumab for Corneal Neovascularization after Burn Injury
Purpose: We report two cases of corneal neovascularization (NV) after burn injury successfully treated by subconjunctival bevacizumab injections at 2-week intervals.Case summary: Three bi-weekly subconjunctival injections of bevacizumab were administered to two patients with corneal NV after burn injury. In our first patient, corneal NV was markedly reduced by bevacizumab injection. The patient exhibited with a clear cornea and improved visual acuity (20/30) after treatment. Eleven weeks after the last injection, the cornea remained clear, with clinical regression of smaller vessels; the improvement in visual acuity was maintained. In the second case, the diameter of the vessels, hemorrhagic lesions, and corneal edema decreased/regressed, with improvement of the visual acuity to 20/25; these improvements persisted for 12 weeks after the last subconjunctival injection.Conclusions: Our results suggest that bi-weekly subconjunctival injection of bevacizumab is well-tolerated and effective for inhibiting chronic corneal NV after burn injury.
- 25 December 2021
- Published by The Korean Optometry Society and The Korean Contact Lens Study Society in Annals of Optometry and Contact Lens
- Vol. 20 (4) , 164-168
Open AccessBi-weekly Subconjunctival Injection of Bevacizumab for Corneal Neovascularization after Burn Injury
Purpose: We report two cases of corneal neovascularization (NV) after burn injury successfully treated by subconjunctival bevacizumab injections at 2-week intervals.Case summary: Three bi-weekly subconjunctival injections of bevacizumab were administered to two patients with corneal NV after burn injury. In our first patient, corneal NV was markedly reduced by bevacizumab injection. The patient exhibited with a clear cornea and improved visual acuity (20/30) after treatment. Eleven weeks after the last injection, the cornea remained clear, with clinical regression of smaller vessels; the improvement in visual acuity was maintained. In the second case, the diameter of the vessels, hemorrhagic lesions, and corneal edema decreased/regressed, with improvement of the visual acuity to 20/25; these improvements persisted for 12 weeks after the last subconjunctival injection.Conclusions: Our results suggest that bi-weekly subconjunctival injection of bevacizumab is well-tolerated and effective for inhibiting chronic corneal NV after burn injury.